MBX Biosciences, Inc. (NASDAQ:MBX) Stock Rated “Moderate Buy” by Sell-Side Analysts

MBX Biosciences, Inc. (NASDAQ:MBX) has been given a consensus recommendation of “Moderate Buy” by the thirteen ratings firms that are covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $87.00.

Several research firms have issued reports on MBX. Wall Street Zen downgraded MBX Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. JPMorgan Chase & Co. initiated coverage on shares of MBX Biosciences in a report on Friday, August 21st. They issued an “overweight” rating and a $88.00 target price for the company. Barclays reissued an “overweight” rating and issued a $88.00 target price on shares of MBX Biosciences in a research report on Friday, August 7th. Mizuho boosted their price target on shares of MBX Biosciences from $57.00 to $91.00 and gave the company an “outperform” rating in a report on Wednesday, July 29th. Finally, Stifel Nicolaus boosted their price target on shares of MBX Biosciences from $70.00 to $84.00 and gave the company a “buy” rating in a report on Monday, October 12th.

MBX Biosciences Stock Performance

Shares of NASDAQ:MBX opened at $56.33 on Friday. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of -18.35 and a beta of 0.17. MBX Biosciences has a 1-year low of $23.07 and a 1-year high of $72.64. The company has a 50 day moving average price of $56.08 and a 200 day moving average price of $46.10.

MBX Biosciences (NASDAQ:MBX) last posted its quarterly earnings results on Monday, November 9th. The company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.49). On average, sell-side analysts expect that MBX Biosciences will post -3.10 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new position in shares of MBX Biosciences in the second quarter worth $183,467,000. Wellington Management Group LLP increased its stake in MBX Biosciences by 55.9% in the second quarter. Wellington Management Group LLP now owns 4,977,523 shares of the company’s stock valued at $274,759,000 after acquiring an additional 1,785,699 shares during the period. Parkman Healthcare Partners LLC bought a new position in shares of MBX Biosciences during the 2nd quarter worth approximately $44,170,000. Stempoint Capital LP boosted its stake in shares of MBX Biosciences by 535.8% in the 1st quarter. Stempoint Capital LP now owns 499,469 shares of the company’s stock valued at $14,909,000 after purchasing an additional 420,916 shares in the last quarter. Finally, Bank of America Corp DE bought a new stake in shares of MBX Biosciences in the 2nd quarter worth about $16,501,000.

MBX Biosciences Company Profile

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for endocrine and metabolic disorders. The company’s research focuses on conditions in which naturally occurring hormones are deficient or do not function adequately. MBX uses its Precision Endocrine Peptide (PEP) platform to design peptide medicines intended to provide more durable hormone activity. Its lead candidate, MBX 2109, is being developed as a long-acting parathyroid hormone replacement therapy for people with chronic hypoparathyroidism.